Docoh
Loading...

PRLD Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.

PRLD stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 Aug 21
27 Oct 21
31 Mar 22
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 343.12M 343.12M 343.12M 343.12M 343.12M
Cash burn (monthly) 6.62M (positive/no burn) 9.31M 7.29M 1.35M
Cash used (since last report) 26.06M n/a 36.61M 28.68M 5.29M
Cash remaining 317.06M n/a 306.51M 314.44M 337.83M
Runway (months of cash) 47.9 n/a 32.9 43.1 251.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
13 Oct 21 Sandor Victor Director Stock Option Common Stock Grant Acquire A No No 15.81 8,022 126.83K 8,022
5 Oct 21 David J Mauro Common Stock Sell Dispose S No Yes 32.0637 1,289 41.33K 0
5 Oct 21 David J Mauro Common Stock Sell Dispose S No Yes 31.303 7,803 244.26K 1,289
5 Oct 21 David J Mauro Common Stock Sell Dispose S No Yes 30.2577 5,908 178.76K 9,092
5 Oct 21 David J Mauro Common Stock Option exercise Acquire M No No 1.89 15,000 28.35K 15,000
5 Oct 21 David J Mauro Employee Stock Option Common Stock Option exercise Dispose M No No 1.89 15,000 28.35K 137,610
7 Sep 21 David J Mauro Common Stock Sell Dispose S No Yes 37.7876 4,640 175.33K 0
7 Sep 21 David J Mauro Common Stock Sell Dispose S No Yes 36.9234 2,873 106.08K 4,640
7 Sep 21 David J Mauro Common Stock Sell Dispose S No Yes 35.9112 7,487 268.87K 7,513
7 Sep 21 David J Mauro Common Stock Option exercise Acquire M No No 1.89 15,000 28.35K 15,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

73.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 55 59 -6.8%
Opened positions 9 17 -47.1%
Closed positions 13 9 +44.4%
Increased positions 23 29 -20.7%
Reduced positions 12 9 +33.3%
13F shares
Current Prev Q Change
Total value 37.82B 29.33B +28.9%
Total shares 34.43M 32.52M +5.9%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Baker Bros. Advisors 10.12M $289.85M 0.0%
Orbimed Advisors 10.04M $287.44M 0.0%
FMR 6.55M $187.6M +4.8%
Ubs Global Asset Management Americas 1.29M $36.87B +100.3%
Vanguard 1.13M $32.24M +29.8%
STT State Street 1.05M $30.13M +20.5%
BLK Blackrock 702.84K $20.12M +3.1%
Hillhouse Capital Advisors 583.33K $16.7M -6.9%
TROW T. Rowe Price 400.8K $11.48M -5.2%
Logos Global Management 400K $11.45M NEW
Largest transactions
Shares Bought/sold Change
Ubs Global Asset Management Americas 1.29M +644.76K +100.3%
Logos Global Management 400K +400K NEW
FMR 6.55M +300.39K +4.8%
Vanguard 1.13M +258.63K +29.8%
STT State Street 1.05M +178.84K +20.5%
MS Morgan Stanley 132.17K +108.09K +449.0%
Massachusetts Financial Services 375.17K +94K +33.4%
Hillhouse Capital Advisors 583.33K -43.17K -6.9%
Marshall Wace 0 -29.32K EXIT
GS Goldman Sachs 18.62K -24.89K -57.2%

Financial report summary

?
Management Discussion
  • Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
  • You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this Form 10-K. Some of the information contained in this discussion and analysis contains forward-looking statements that involve risks and uncertainties. You should review the section titled “Risk Factors” in this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described below.
  • We are a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. By leveraging our core competencies in cancer biology and medicinal chemistry, combined with our target class- and technology platform-agnostic approach, we have built an efficient, fully-integrated drug discovery engine to identify compelling biological targets and create new chemical entities, or NCEs, that we rapidly advance into clinical development. We believe our approach could result in better targeted cancer therapies. Our discovery excellence has been validated by our rapid progress in creating a wholly-owned, internally developed pipeline. Since our inception in 2016, we have received clearance from the U.S. Food and Drug Administration, or the FDA, for four investigational new drug applications, or INDs, and successfully advanced three of these programs into clinical development, with the fourth expected to begin clinical development in the first half of 2021. In addition, we have three unique programs in various stages of preclinical development that we plan to advance into clinical development beginning in 2021.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg